These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 9749072)
1. [Treatment of cancer of the bladder in Québec. Results of a multicenter survey]. Brochet F Cancer Radiother; 1998 Apr; 2 Suppl 1():17s-18s. PubMed ID: 9749072 [No Abstract] [Full Text] [Related]
2. [Immunotherapy with oral BCG in cancer of the bladder]. Netto Júnior NR; de Salvo Reinato JA; Teixeira LC; De Bellis N AMB Rev Assoc Med Bras; 1978 Oct; 24(10):358-60. PubMed ID: 311054 [No Abstract] [Full Text] [Related]
3. Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS). Lamm DL J Urol; 2000 Jun; 163(6):1890-1. PubMed ID: 10799217 [No Abstract] [Full Text] [Related]
15. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448 [TBL] [Abstract][Full Text] [Related]
16. Controversial issues and optimal management of stage T1G3 bladder cancer. Metwalli AR; Kamat AM Expert Rev Anticancer Ther; 2006 Aug; 6(8):1283-94. PubMed ID: 16925494 [TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy in superficial bladder carcinoma]. Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392 [TBL] [Abstract][Full Text] [Related]
18. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Brake M; Loertzer H; Horsch R; Keller H J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163 [TBL] [Abstract][Full Text] [Related]
19. Bladder cancer. Treatments improving. Mayo Clin Health Lett; 2003 Oct; 21(10):1-3. PubMed ID: 14619780 [No Abstract] [Full Text] [Related]
20. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]